With the collaboration of: ![]() Topics to be discussed: • What can CDTI do for R&D activities for biotechnology companies? • Supporting internationalization of biotech companies through technological cooperation. • Opportunities for biotechnology in Horizon 2020 - Horizon Europe. • Non-dilutive funding from US Federal Agencies and Private Foundations. Chairperson: ![]() Cecilia Hernández Head of Department -Health, Bioeconomy, Climate & Natural Resources. CDTI -Centre for the Development of Industrial Technology (Spain) Physicist at Universidad Autonoma de Madrid. CSIC Instituto de Ciencia y Tecnología de Polimeros. Production and R&D departments at Private Company Joined CDTI in 1991. Different responsibilities : Spanish representative to several European Union Framework R&D Programmes as well as to the European Space Agency. Speakers: ![]() "NIH/DOD Non-Dilutive Funding Opportunities - Non-US Applicants Welcome"
Jonathan Adalist Head of Business Development Freemind Group (USA) Jonathan Adalist, Head of Business Development at FreeMind, has been with the firm since 2014 and has comprehensive experience and an extensive understanding of the non-dilutive funding landscape in the US. Before joining FreeMind, Jonathan held various marketing and sales positions having done business in the US, Central and South America, Europe, and the Middle East. Jonathan holds a B.Sc. in Biology and an M.Sc. in Biotechnology and Molecular Biology from Tel-Aviv University. ![]() “CDTI RTDI (Research, Technology Development and Innovation) funding Instruments” Juan Luis Romera Management, promotion & expert advice of R+D +i projects – Health. Department of Health, Bioeconomy, Climate and Natural Resources CDTI -Centre for the Development of Industrial Technology (Spain) Juan Luis has more than 20 years of work experience, the last 12 years at CDTI. Before joining CDTI, Juan Luis has worked in different position: Toledo Hospital (Clinical Analysis Doctor (Practitioner)), in the pharmaceutical industry (as scientist at Johnson and Johnson Pharmaceutical Research and Development) and as researcher at University of Granada. Juan Luis holds a PhD in Organic and Pharmaceutical Chemistry from University of Granada. ![]() "Opportunities for Biotechnology in Horizon 2020" Marta Gómez Spanish Representative in Horizon 2020 – Societal Challenge 1 Health, demographic change and wellbeing and in the Innovative Medicines Initiative (IMI) CDTI -Centre for the Development of Industrial Technology (Spain) Biologist with a Master in Biotechnology (Business Administration for Biotech Companies). She has been working since 2003 for the Spanish Centre for the Development of Industrial Technology (CDTI), a public company within the Ministry of Science, Innovation and Universities; the Business Innovation Financing Agency. Marta’s work is fully dedicated to Horizon 2020 in the EU Programmes Division, being the Spanish Representative in Horizon 2020–Societal Challenge 1 Health, demographic change & wellbeing & in the Innovative Medicines Initiative (IMI), where she is the elected vice chair of the States Representatives Group since 2015. Download Presentation “Regional public support for R & D in Andalusia” José A. Pascual Sánchez
Head of Innovation and Programmes Unit The Innovation and Development Agency of Andalusia (IDEA Agency) |
11:00 - Ability Pharmaceuticals (Spain) 11:10 - Avivagen (Canada) 11:20 - Biohope (Spain) 11:30 - Bioquochem (Spain) 11:40 - Cristal Pharmaceuticals (Netherlands) 11:50 - Cannabiotics: exploring the antitumor effect of cannabinoids in hematologic malignancies - Institute of Biomedicine of Seville/University Hospital Virgen del Rocio(Spain) |
Sponsored by:
The number of financing agreements and M&A in the early stages is increasing in the life sciences. Investing early is risky, but it also gives you the opportunity to build the asset in a very direct way. Chairwoman: “Keys to invest in early stage biopharma” Clara Campàs Moya
Partner & co-founder Asabys Partners (Spain) Dr. Clara Campàs-Moya is partner and co-founder at the recently created venture capital firm ASABYS Partners (Barcelona). Formerly, she served as Strategy & Development Director at Kern Pharma (2014-2018) and as a managing director at Advancell. Dr. Campàs has served as a member of the Investment Committee of the venture capital firm HealthEquity, as well as vice-president of CataloniaBIO, and acts as a mentor in several programs such as d-Health MOEBIO, Caixaimpulse and the BCN Mentoring Program. Dr. Campàs-Moya is the co-author of the Acadesine patent (the first Spanish patent from a public University reaching clinical trials successfully). Up to 2006 Dr. Campàs-Moya was a researcher engaged in the development of new therapies in cancer. Dr. Campàs-Moya has published extensively in peer-reviewed scientific journals as well the medical literature. She received her Doctorate in Pharmacy in 2004 and a Master’s in Pharmacy from the University of Barcelona in 1999. Download Presentation Speakers: ![]() “Investing in ‘build’ vs. ‘growth” Marco Boorsma General Partner Forbion Capital (The Netherlands) Marco is General Partner at Forbion and has a key role in the investment team with focus on biopharma and a special interest to bring his background in molecular biology, operational and business development experience from both small and large businesses to the portfolio. He currently serves on the boards of several of Forbion portfolio companies, and was instrumental in starting-up, investing and the sale of recent portfolio companies such as NorthSea, Prexton, Dezima and Akarna. “Funding Biotech companies in the early stages: Equity crowdfunding and co-investment with business angels and VCs” Daniel Oliver
Director Capital Cell (Spain) Biology Degree, Universitat de Barcelona, specializing in Biomedical Sciences. Founder and CEO, Capital Cell (Europe’s 1st Life Sciences investment platform). President, Spanish Crowdfunding Association, between July 2014 and September 2016. Member of the European Stakeholders Forum. Advisor to the European Commission on alternative financing legislation since January 2015. Founding member and Board of Directors, European Equity Crowdfunding Association. Professor of entrepreneurship and business financing in Barcelona Activa. “Public Funding in Andalusia”
Manuel Rodriguez
Project Manager
Venture Invercaria (Spain) Since 2005,Manuel Rodriguez is Investment Director at INNOVA VENTURE SGECR, S.A., a public venture capital company owned by the Regional Government of Andalucia focused in early stages (seed and start-up), analyzing business plan of more than 500 companies, supervising and elaborating the evaluation documents and the proposal of investment definition, negotiating the shareholders' agreement and monitoring the investment from the Board of Directors. Graduated in Economics Universidad Complutense de Madrid.
“Maximizing investment value through Clinical Development Strategy”
José González Martínez
Associate Principal, Consulting Services
IQVIA (Spain) José González is Associate Principal within IQVIA’s Strategic Consulting Team. He has a track record of more than 10 years and is specialized in advising companies in the Pharma and Biotech industries, valuation of investment opportunities in the health sector, long term corporate strategy and new market entry strategy. He holds a degree in Business Administration and environmental sciences from the Universidad Autónoma de Madrid and a MBA from Duke University. |
15:15 - Tetraneuron (Spain) 15:25 - Vaxdyn (Spain) 15:35 - Versantis (Switzerland) |
16:15 Johnson & Johnson ![]() “External Innovation from Jonhon & Johnson” Antonio Gomez New Ventures Lead Johnson & Johnson (Spain) Antonio Gomez has almost 20 years of experience in the Pharma industry. Right before getting a PhD in Synthetic Organic chemistry from the University of Salamanca he joined the Janssen R&D group in Toledo as a medicinal chemist in 1996. In 2000 he spent one year in the Research Support group of Janssen Pharmaceutica at Beerse, Belgium. Then, he came back to Toledo, where he has held different positions coordinating first the internal projects, then the scientific IT with a special role in the development of the Janssen R&D Electronic Lab Notebook and, since 2012, the external collaborations. Starting in late 2013 this role has been integrated into the position of New Ventures Lead in Spain for the London Johnson & Johnson Innovation Center. As such he is in charge of scouting the Spanish scientific landscape and setting up collaborations in the country. 16:25 Eli Lilly and Company: "BIC Cassette as a New Tool to Enable Novel Biological Targets" ![]() Maria Angeles Martinez Grau Senior Research Advisor, Medicinal Chemistry and External Innovation Eli Lilly and Company (Spain) Maria Angeles received her doctorate in Organic Chemistry from Universidad Complutense in 1994 and the “National Award for Young Investigators” (RSEQ) in 1995. After two years of postdoctoral research at the University of Pittsburgh, she became Associate Professor at Universidad Complutense. Maria Angeles joined Lilly in 1998 at the Spanish site and accepted an assignment for three years in Indianapolis. As medicinal chemist, she has contributed to deliver 12 clinical candidates in the areas of Neuroscience, Obesity and Diabetes. In 2017, she accepted the role of Coordinator of External Innovation in Europe in addition to her scientific responsibilities. Download Presentation 16:35 MSD "Collaborating and partnering with MSD” ![]() Phil L’Huillier Head of Business Development, Europe & Middle East MSD (United Kingdom) Phil is Head of Business Development, Europe & Middle East for Merck, Sharpe & Dohme (MSD), based in London. He is a seasoned business development professional with 15+ years’ experience in the biotech/pharma industry, in R&D, licensing/partnering, new company formation and M&A. Prior to joining MSD, Phil was an Executive Director at Cancer Research Technology Ltd. Phil has previously been a director of numerous start-ups including Achilles Therapeutics, Artois Pharma, PsiOxus Therapeutics and BliNK BioMedical. Prior to CRT, Phil headed up global licensing at BioFocus Discovery Ltd, an AIM-listed integrated early stage drug discovery company. Phil holds an MBA, and a PhD in cellular and molecular biology. 16:45 Novartis Pharma AG “Your partner of choice” ![]() Begoña Carreno WorldWide Head BD&L Respiratory Novartis Pharma AG (Switzerland) Begoña Carreño PhD, is currently the World Wide BD&L Head in the Respiratory Franchise at Novartis Pharma AG, based in Basel, Switzerland. Begoña has been at Novartis for 14 years, mainly within the BD&L function managing different therapeutic areas. Before joining Novartis, she was the Head of External Pharmaceutical projects at Almirall (Barcelona, Spain). Begoña holds a PhD in Drug Delivery from the London School of Pharmacy (UK) and a BSc in Biochemistry from Keele University (UK). She is married with two children, Carla (5) and Santiago (2) that keep her occupied in her spare time. |
Biobanking has become an important resource for healthcare research, medical care, and drug discovery. The kinds of questions being addressed in contemporary medical research depend upon the availability of biological tissue samples along with associated clinical data including medical, ´omics, genealogical, and lifestyle information. International awareness of the need for biobanks has increased, in part, because of the growing promise of research related to the development of personalized medicine, especially in oncology. Identification of biomarkers that are specifically associated with particular medical conditions such as cancer, cardiovascular disease, rare diseases and neurological disorders, among others, are useful for early detection, prevention, and treatment of the diseases. The ability to determine individual biomarkers and to use those biomarkers for disease diagnosis, prognosis and prediction of response to therapy is having a very significant impact on personalized medicine and is rapidly changing the way clinical care is conducted. As a critical requirement for personalized medicine is the availability of a large collection of patient samples with well annotated patient clinical and pathological data, biobanks thus play an important role in personalized medicine advancement. Identification and validation of disease-relevant biomarkers is essential to developing diagnostic, prognostic, and therapeutic applications that will improve community health and protect the public from illnesses. For these purposes, high-quality and well-annotated tissue sample collections housed in specialized bio-repositories must be available. The most important aspects of a biobank are consistency and quality. The validity of the data generated by biobanked samples depends on their quality, which is in turn dependent on the use of stringent standards in collecting the biospecimens and delineating patient characteristics. Variations associated with collecting, processing and storing different samples and the accompanying clinical data, make it extremely difficult to extrapolate or to merge data from different studies. Therefore, the standardisation and harmonisation of biobanking practices are of paramount importance. The need for data grows strongly. It demands the gathering and administration of large collections of samples and related data, often from multiple sources. Hence, ‘virtual biobanks’ started forming with international collaboration and geographically distributed forms of endeavour. Although researchers worldwide recognize European biobanks as important resources, obstacles to their efficient use exist. Critical points are the fragmentation of sample collections and a lack of harmony among technical, ethical, and legal requirements. Data sharing across biobanks and research programs will be very important in the future of medical research to better understand individual differences in disease development, progression of disease, and response to treatment. Enabling such data sharing while protecting the privacy of individual research participants is a major challenge for the future. Biobanks will need to address data standards, metadata requirements, data quality, and how data are stored and accessed. Challenges mentioned above and the impact of collaborative biobanking infrastructures in the framework of Horizon 2020 and beyond will be discussed. Chairperson: Manuel Rodríguez: Scientific Director Andalusian Public Health System Biobank (SSPA) (Spain) Speakers: Cristina Villena Coordinator National Biobanks Network Platform - PRNB (Spain) Victor González R&D Director Atrys Health (Spain) Francesco Florindi Engagement Officer BBMRI-ERIC (Austria)
Biobanking has become an important resource for healthcare research, medical care, and drug discovery. The kinds of questions being addressed in contemporary medical research depend upon the availability of biological tissue samples along with associated clinical data including medical, ´omics, genealogical, and lifestyle information. International awareness of the need for biobanks has increased, in part, because of the growing promise of research related to the development of personalized medicine, especially in oncology. Identification of biomarkers that are specifically associated with particular medical conditions such as cancer, cardiovascular disease, rare diseases and neurological disorders, among others, are useful for early detection, prevention, and treatment of the diseases. The ability to determine individual biomarkers and to use those biomarkers for disease diagnosis, prognosis and prediction of response to therapy is having a very significant impact on personalized medicine and is rapidly changing the way clinical care is conducted.
As a critical requirement for personalized medicine is the availability of a large collection of patient samples with well annotated patient clinical and pathological data, biobanks thus play an important role in personalized medicine advancement. Identification and validation of disease-relevant biomarkers is essential to developing diagnostic, prognostic, and therapeutic applications that will improve community health and protect the public from illnesses. For these purposes, high-quality and well-annotated tissue sample collections housed in specialized bio-repositories must be available.
The most important aspects of a biobank are consistency and quality. The validity of the data generated by biobanked samples depends on their quality, which is in turn dependent on the use of stringent standards in collecting the biospecimens and delineating patient characteristics. Variations associated with collecting, processing and storing different samples and the accompanying clinical data, make it extremely difficult to extrapolate or to merge data from different studies. Therefore, the standardisation and harmonisation of biobanking practices are of paramount importance.
The need for data grows strongly. It demands the gathering and administration of large collections of samples and related data, often from multiple sources. Hence, ‘virtual biobanks’ started forming with international collaboration and geographically distributed forms of endeavour.
Although researchers worldwide recognize European biobanks as important resources, obstacles to their efficient use exist. Critical points are the fragmentation of sample collections and a lack of harmony among technical, ethical, and legal requirements.
Data sharing across biobanks and research programs will be very important in the future of medical research to better understand individual differences in disease development, progression of disease, and response to treatment. Enabling such data sharing while protecting the privacy of individual research participants is a major challenge for the future. Biobanks will need to address data standards, metadata requirements, data quality, and how data are stored and accessed.
Challenges mentioned above and the impact of collaborative biobanking infrastructures in the framework of Horizon 2020 and beyond will be discussed.
Chairperson:
Manuel Rodríguez: Scientific
Director
Andalusian Public Health System Biobank (SSPA) (Spain)
Speakers:
Cristina Villena
Coordinator
National Biobanks Network Platform - PRNB (Spain)
Victor González
R&D Director
Atrys Health (Spain)
Francesco Florindi
Engagement Officer
BBMRI-ERIC (Austria)
Biobanking has become an important resource for healthcare research, medical care, and drug discovery. The kinds of questions being addressed in contemporary medical research depend upon the availability of biological tissue samples along with associated clinical data including medical, ´omics, genealogical, and lifestyle information. International awareness of the need for biobanks has increased, in part, because of the growing promise of research related to the development of personalized medicine, especially in oncology. Identification of biomarkers that are specifically associated with particular medical conditions such as cancer, cardiovascular disease, rare diseases and neurological disorders, among others, are useful for early detection, prevention, and treatment of the diseases. The ability to determine individual biomarkers and to use those biomarkers for disease diagnosis, prognosis and prediction of response to therapy is having a very significant impact on personalized medicine and is rapidly changing the way clinical care is conducted.
As a critical requirement for personalized medicine is the availability of a large collection of patient samples with well annotated patient clinical and pathological data, biobanks thus play an important role in personalized medicine advancement. Identification and validation of disease-relevant biomarkers is essential to developing diagnostic, prognostic, and therapeutic applications that will improve community health and protect the public from illnesses. For these purposes, high-quality and well-annotated tissue sample collections housed in specialized bio-repositories must be available.
The most important aspects of a biobank are consistency and quality. The validity of the data generated by biobanked samples depends on their quality, which is in turn dependent on the use of stringent standards in collecting the biospecimens and delineating patient characteristics. Variations associated with collecting, processing and storing different samples and the accompanying clinical data, make it extremely difficult to extrapolate or to merge data from different studies. Therefore, the standardisation and harmonisation of biobanking practices are of paramount importance.
The need for data grows strongly. It demands the gathering and administration of large collections of samples and related data, often from multiple sources. Hence, ‘virtual biobanks’ started forming with international collaboration and geographically distributed forms of endeavour.
Although researchers worldwide recognize European biobanks as important resources, obstacles to their efficient use exist. Critical points are the fragmentation of sample collections and a lack of harmony among technical, ethical, and legal requirements.
Data sharing across biobanks and research programs will be very important in the future of medical research to better understand individual differences in disease development, progression of disease, and response to treatment. Enabling such data sharing while protecting the privacy of individual research participants is a major challenge for the future. Biobanks will need to address data standards, metadata requirements, data quality, and how data are stored and accessed.
Challenges mentioned above and the impact of collaborative biobanking infrastructures in the framework of Horizon 2020 and beyond will be discussed.
Chairperson:
Manuel Rodríguez: Scientific
Director
Andalusian Public Health System Biobank (SSPA) (Spain)
Speakers:
Cristina Villena
Coordinator
National Biobanks Network Platform - PRNB (Spain)
Victor González
R&D Director
Atrys Health (Spain)
Francesco Florindi
Engagement Officer
BBMRI-ERIC (Austria)
10:00 - 10:15 PART 1. INTRODUCTION
Challenges for Crop Biotechnology in EuropeSoledad de Juan Arechederra Director, Radio Program Onda Agraria & Manager Onda Cero Radio (Spain) & Fundación Antama Soledad de Juan Arechederra is an Agronomist from the Polytechnic University of Madrid with more than twenty years of experience in agronomy. For the last 15 years, she has been developing her work in the area of communication in the agri-food sector. She currently directs the ANTAMA Foundation, a non-profit organization whose purpose is the promotion of new technologies applied to agriculture, the environment and food, bringing the reality of green bioltechnology closer to media, agricultural sector, society, educators and anyone interested in the development of biotechnology. Soledad de Juan Arechederra makes this activity compatible with the co-direction for more than 15 years of the ONDA AGRARIA program, a national broadcast radio programme in the area of agriculture, livestock, fisheries, food, rural development and environment in ONDA CERO RADIO. 10:15 - 11:00 PART 2. CHALLENGES IN THE AGROFOOD INDUSTRY ![]() Graham Brookes Agricultural Economist PG Economics Ltd (UK) Graham is an agricultural economist and consultant with more than 30 years’ experience of examining economic issues relating to the agricultural and food sectors. He is a specialist in analyzing the impact of technology, policy changes and regulatory impact. He has, since the late 1990s, undertaken a number of research projects relating to the impact of agricultural biotechnology and written widely on this subject in peer reviewed journals. This work includes annual updates of a global economic and environmental impact of GM crops report, the impact of insect resistant maize in Spain and herbicide tolerant soybeans in Romania, the impact of GMO labelling and ‘GMO avoidance’ in Europe, the economic impact of GMO zero tolerance legislation in the EU, the cost to the UK economy of failure to embrace agricultural biotechnology, the economic impact of bio-safety legislation in Turkey and studies of the potential impact of using crop biotechnology in the Ukraine, Russia, Thailand, Indonesia and Vietnam. ![]() “Transforming industries: new technology innovation in the Agrofood Industry” Ignasi Papell Business Development Manager Food Industry Eurecat – Technology Center (Spain) Ignasi is a Chemical Engineer with experience in business innovation and R&D projects, at both European and national level, in particular in the field of the food industry. Passionate about business development, new technologies, innovation and technology transfer, he is currently responsible for the food sector in Eurecat Technology Center. Biotechnology, industrial technologies and digitalisation are relevant areas when facing the CHALLENGES IN THE AGROFOOD INDUSTRY. Download Presentation ![]() "Mediterranean Horticulture facing Bioeconomy” Paco Egea
Professor of Analytical Chemistry
University of Almeria (Spain)
Francisco Egea is professor of analytical chemistry at the University of Almeria, Spain. Expert in food safety and greenhouse agricultural practices. He has published 55 papers in peer reviewed scientific journals and co-founded a spin-off company related with advanced analytical services. He has been Vice-chancellor of RTD at the Univerisity of Almeria, Director of the Knowledge Transfer Office at the same university, and deputy director of the Research Centre of Agri-food Biotechnology (BITTAL). He has been Detached National Expert in a training programme at the Sustainable Agricultural Unit of the Directorate General Development and Cooperation of the European Commission and takes part as expert of the European Innovation Partnership EIPAGRI focus group “Circular Horticulture“.
11:00 -11:45 - PART 3. BIOTECHNOLOGY SOLUTIONS FOR THE AGROALIMENTARY INDUSTRY ![]() Current and future biotechnological tools applied to plant breeding Jordi García-Mas Plant and Animal Genomics Program Center for Research in Agricultural Genomics – CRAG (Spain) PhD in Biochemistry and Molecular Biology at the Universitat Autònoma de Barcelona (1994) and Marie Curie postdoctoral fellow at the Sainsbury Laboratory (Norwich, UK) (1995-1997) in plant genetics. Since 1997, he is an IRTA researcher and in 2011 he joined the Plant and Animal Genomics Program at the Center for Research in Agricultural Genomics CSIC-IRTA-UAB-UB (CRAG). He is co-author of 76 publications in international peer-reviewed journals. Among other projects, he has coordinated the sequencing of the melon genome (MELONOMICS). He has contrasted experience in the transfer of genetic and genomic tools that are used in breeding programs by seed companies. He has participated in several national and international evaluation panels, regularly teaches in Master and Degree courses and has supervised 7 PhD theses. Download Presentation ![]() Waste valorization: lignocellulosic feedstocks as a sustainable platform for the production of bio-based compounds Eduardo Díaz Environmental Microbiology Group Biological Research Centre, CSIC (Spain) Dr. Eduardo Díaz obtained his PhD in Biology at the Complutense University of Madrid (Spain) in 1991. Following the award of a post-doctoral research fellowship from 1992-1995 he worked at the National Center for Biotechnology (GBF) in Braunschweig (Germany) in the field of environmental microbiology. Since 1999 he is scientific researcher of the CSIC at the Biological Research Centre in Madrid, where he is currently heading the Environmental Microbiology group at the Microbial and Plant Biotechnology Department. He has more than 100 publications in international research journals on the genetics and molecular aspects of the biodegradation/bioconversion of contaminants in bacteria, as well as on the engineering of recombinant biocatalysts for biotechnological purposes. He has teaching experience supervising 14 PhD theses and 7 Master Degrees, and he has been member of several scientific committees of international congresses and selection committees of national research projects. ![]() Functional foods, health claims and personalization Andreu Palou Director of the Laborarory of Molecular Biology, Nutrition and Biotecnology University of the Balearics Islands (Spain) Andreu Palou is Professor of Biochemistry and Molecular Biology at the University of the Balearic Islands (UIB). Head of the Laboratory of Molecular Biology, Nutrition and Biotechnology of the UIB and of the research group "Nutrigenómica y Obesidad" of CIBEROBN (Centro de Investigaciçon Biomédica en Red sobre Obesidad y Nutrición). Author of more than 350 scientific articles and several patents. He has been Vice-president of the Scientific Nutrition Panel of the European Food Safety Authority (EFSA) and vice-president and member of the Scientific Committee on Food. He was the first president of the Scientific Committee of the Spanish Agency for Food Safety and Nutrition (AESAN, actually AESAN) (2003-2010). He has received several awards, including the DuPont Science Award (2014). More information (CV) at: http://palou.uib.es/Andreu-Palou/ |
In the agricultural sector we are currently facing a series of global challenges that we must face with concrete measures; Population growth and food security, dependence on fossil resources to produce and climate change are pushing us towards a new paradigm in food production. In this sense, biotechnology is presented as an opportunity to improve the quality of life, the environment and the generation of qualified employment. The speakers who are going to participate in this session will enlighten us with practical examples that they have implemented in their company or in their research activity. Chairperson: ![]() Pilar Garrido Granados Program and Reports Advisor CAPDER (Spain) Pilar Garrido Granado– Programmes and Reports Consultant in Regional Ministry of Agriculture, Fisheries and Rural Development. She has a Degree on Agrarian Engineering and a Master Degree in Agronomist Engineering. She has worked in different Services in the Regional Ministry of Agriculture (Agrarian Production, Vegetal Health) since 2005. She worked as Technical advisor in the General Secretary's Office of Agriculture and Food and she led the Studies and Statistical Service in the General Secretary's Office of Agriculture and Food. She has planned and coordinates the Studies and Statistics in the agrarian and fishing sectors in Andalusia, coordinating it with other public Administrations and Institutions. She is currently involved in planning and evaluation of policies, with the aim of incorporating the possibilities offered by new technologies and the bioeconomy in the Andalusian agro sector. Speakers: ![]() Ricardo Ortiz Business Manager Rijk Zwaan (Spain) Ricardo Ortiz, has a proven executive management track record and over 20 years of experience driving sales growth and marketing activities in the seed industry as Business Manager of Rijk Zwaan Ibérica, where he leads the implementation of all sales and marketing strategies in the Cluster formed by Spain, Portugal and Morocco countries, making his managerial responsibilities compatible with the coordination of the global pepper development. Rijk Zwaan is amonst the top 5 vegetable breeding companies in the world. The focus is fully on vegetable seeds and offer a wide assortment within the sector. ![]() "Innovations in quality & safety of fresh-cut produce" Giancarlo Colelli Professor, Department of Agriculture, Food and Environmental Sciences University of Foggia (Italy) Full Professor of Equipments for Postharvest Operations at the University of Foggia, Italy, where he also chairs the Doctorate Program on “Innovation Management in Agricultural and Food Systems of the Mediterranean Region”. R&D activities at the University of Foggia primarily include equipment implications on quality of whole and of fresh-cut fruits and vegetables, non-destructive technology for assessment of quality attributes in fresh fruits and vegetables, low impact technologies to extend the shelf-life of fresh fruits and vegetables. As principal investigator he has coordinated more than 20 national and International R&D Projects. In conjuction with other colleagues organized all editions of the European Short-course on Quality & Safety of Fresh-cut Produce (in Italy, Spain, Germany, Turkey, UK; next edition in Portugal). He is author of more than 200 scientific papers on national and international journals and proceedings. ![]() "Algae for a Healthy World” Francisco Javier Fernandez-Acero Vice-Rectorate for Transference and Technological Innovation, General Director, Associate Professor. Laboratory of Microbiology, Institute for Viticulture and Agri-Food Research Marine and Environmental Sciences Faculty (CASEM), CeiA3/CeIMAR University of Cádiz (Spain) Associate Professor of Microbiology, University of Cadiz. Coordinator of the Microbiology Lab at the Research Institute of Viticulture and Agrifood Research (IVAGRO). Research interest: Proteomics approaches to non-model microorganism. Biotechnological applications of non-model environmental microorganisms. |
Sponsored by: ![]() This presentation will highlight the importance of gaining efficacy data early in clinical development and describe how Covance’s approach to hybrid Phase I study designs enables you to add value by inclusion of patients earlier in development. This multidisciplinary approach driven by scientific and medical insight will be illustrated by recent case histories in different therapeutic areas. Speaker: ![]() Amitava Ganguli Medical Director, Medical & Scientific Affairs Covance (UK) >15 years of experience in clinical research and internal medicine. >10 years as an investigator in both healthy volunteers and patients in phase I to IV. PI for renal impairment patient trials. Medical Director roles at 3 MHRA accredited phase I units in the UK. Certified in Clinical Pharmacology and General Internal Medicine; Honorary Senior Lecturer in Clinical Pharmacology and Therapeutics at University of Liverpool. |
Sponsored by: ![]() Over the past years there have been considerable advances in the understanding of the pathogenesis of ophthalmic disorders. This knowledge is being translated to the drug discovery field. A variety of therapeutic approaches like advanced therapies, RNA interference technologies and new peptides will be discussed during the session with a special focus on their future impact in the treatment of severe unsolved diseases. Chairperson: ![]() Andres G. Fernández Director Ferrer Advanced Biotherapeutics (Spain) PhD (Pharmacology; Univ. Barcelona) and MS (Pharmacy Spec. Biochemistry; Univ. Barcelona). Current position: Director of Ferrer Advanced Biotherapeutics at Ferrer. Previous positions: Biotechnology and Biological Sciences, Director (Ferrer); R&D Director & Member of the Board (Salvat); Associate Director of Discovery (Almirall); Associate Professor Cell Biology (UAB); Head of Pharmacology (Almirall). Direct executive and scientific responsibilities on teams successfully developing and launching: 5 New Molecular Entities (EU/USA/ASIA); 1 New Therapeutic Entity in USA/EU and 1 New Molecular DX product in oncology in EU. Co-author of over 40 peer-review publications, 110 communications and lectures and co-inventor of 18 international patent applications. Director of two doctoral theses. Former Chairman of the Program Committee of the International Union of Pharmacology (IUPHAR). Former member of the Board of Directors of ASEBIO. Chairman of the Catalan Society of Medical Biotechnology. Expert Panel Member and Mentor in CaixaImpulse Programme. Member of the Scientific Advisory Board at BIONAND. Member of the Scientific Committee of multiple Congresses and Meetings. Member of the Jury of various Scientific Awards. Frequent Invited Speaker at many Scientific or Academic events. Current interests: Open innovation & Collaborative Bio-Research. Advanced Therapies. Neuropharmacology. Ophthalmology. Molecular diagnostics. Research policies & sustainability. Speakers: ![]() "Oligonucleotide-based therapies. Development of RNAi compounds for the treatment of ocular conditions" Ana Isabel Jiménez COO, R&D Director Sylentis (Spain) Ana Isabel Jimenez obtained her Ph.D. in Biological Sciences from the Complutense University and MS in Biological Sciences (Spec. Biochemistry) from the Complutense University. She also obtained a Management Development Program diploma from the EOI Business School in Madrid. She completed post-doctoral training at the Department of Molecular Pathology National Cancer Research Center (CNIO) where she was author of several publications of international relevance. In 2003, she joined Genomic SAU (Zeltia group) in the position of Senior Researcher in R&D Department. In 2006, she was appointed Director of Research & Development at Sylentis (Zeltia group). She was promoted to her current position Chief Operations Officer at Sylentis (Pharmamar group) in 2013 where she is direct executive and scientific responsibilities on teams successfully developing drugs based on RNA interference for different pathologies. Co-author of over 20 peer-review publications, 50 communications and lectures, co-inventor of 16 international patent applications and more than 15 funded research programs. Mentor in the Mentoring program USC (Santiago Compostela University). Lecturer in postgraduate programs in the field of health in CESIF, Carlos III University, CEU, Aliter and IUCT. Lecturer in Biotechnology degree in Francisco de Vitoria University. Current interests: R&D. Oligonucleotides. RNA Interference. Drug development. Preclinical Models. Nanotecnology. Bio-informatics. Open innovation. Ophthalmology. Rare Diseases. Molecular Biology. Intellectual Property. ![]() "New perspectives in retinal degenerative diseases" José Carlos Pastor Director IOBA - Valladolid Cell Therapies (Spain) MD (University of Navarra, Pamplona, 1974); PhD (university of Navarra, Pamplona, 1975). Specialist in Ophthalmology (University of Zaragoza, 1976). Full professor of Ophthalmology (University of Santiago de Compostela, 1979); Chairman of Ophthalmology (University of Valladolid, 1981). Founder of the IOBA (Eye Institute, University of Valladolid, 1994). Vice-Chancellor of Research (1987-1991, University of Valladolid). Current position: Full professor of Ophthalmology (University of Valladolid) and Chairman of Ophthalmology (Hospital Clinico Universitario, Valladolid), Director of the Retina Group at IOBA (Recognized Research Group by the University of Valladolid and Consolidated Research Unit by the Regional Government). General Coordinator of Oftared (Cooperative Research Network, Carlos III Institute of Health). Co-inventor of 8 patent applications. Author of 259 publications (120 in indexed journals), more than 500 communications and 32 books or chapters. Director of 43 doctoral thesis. Six stretches of research (six-year period) recognized by the Ministry of Science. Member of the Editorial Board of 12 scientific journals. Editor in Chief of the Spanish Journal of Ophthalmology (1995-2000), during that time journal was indexed and included in PubMed. Reviewer of 16 scientific journals. Member of the Biomedical Sciences Advisory Committee of the National Commission to Evaluate the Research Activity (2004-2006). 33 national and internationals awards (among them the Regional Annual Medal in Scientific and Technical Research and Innovation, Junta de Castilla y Leon, 2016). Reviewer of research projects for several National and International Agencies (FP7, Cordis EX2006C170303, of the European Union in the area of Health, Argentinian Ministry of Science). National expert of the CTN91 Committee of ISO standards (2018). Founder and Scientific Director of Vision R&D (first spin-off of the University of Valladolid). Lines of Research: Diabetic retinopathy, retinal detachment, vitreous substitutes, cell therapy for retinal diseases. Patron of the RetinaPlus Foundation, Spanish Ophthalmological Society Foundation and Jimenez-Arellano (University of Valladolid) Foundation. Download Presentation ![]() "GPCR-based therapies. GLP-1 in diabetic retinopathy" Rafael Simó Head of the Endocrinology and Nutrition Service VHIR - Hospital Vall d'Hebron (Spain) Dr. Rafael Simó is the Director of Diabetes and Metabolism Research Unit at Vall d’Hebron Research Institute (VHIR), Head of the Endocrinology Department at Vall d’Hebron University Hospital, and Professor of Medicine & Endocrinology at the Autonomous University of Barcelona. His group belongs to CIBERDEM (the Spanish network for the research of diabetes and associated metabolic diseases). Prof. Simó has authored over 200 articles related to diabetes which have been published in high-profile peer-reviewed journals, besides 12 book chapters. He has participated in 22 research projects related to diabetic retinopathy and in 28 projects related to clinical diabetes. Prof. Simó is the Coordinator of the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR) (HEALTH-2011-FP7-278040). This consortium (constituted by 19 partners all of them leaders in diabetic retinopathy from 8 different countries) was funded by the EC for developing the first clinical trial using neuroprotective agents topically administered to prevent or arrest the development of diabetic retinopathy. In addition, Prof. Simó is the Diabetologist of Expert Committee on Diabetic Retinopathy and Vascular Diseases of the EVICR.net (European Vision Clinical Research). Prof. Simó is President of the European Association for the Study of Diabetes-Eye complications (EASD-ec), and renowned worldwide for his contributions to the pathophysiology of diabetic complications, in particular diabetic retinopathy. Prof. Simó received the Spanish Society of Diabetes Award (Rodríguez Miñón Award-2008) for a career in the field of Clinical Research in Diabetes, the “Dr. Josep Trueta” Award of the Academy of Medical Sciences from Catalonia (2011) for his innovative contributions in Biomedicine, and the Award of the Spanish Society of Endocrinology (2015) for the development and consolidation of a high-quality research group. |
![]() Foro Capital Pymes, entity awarded by the European Commission as the best proposal in Europe for alternative financing for SME companies, will offer to 8 selected companies, the opportunity to present their investment proposals to the investment community, composed of Venture Capital, Family Office, Capital Risk, Corporate ... Each company will have 10 minutes to present their investment proposal plus a round question of 5 minutes. Companies that want to submit to investors in the forum, should download the executive summary form at www.forocapitalpymes.com and send it filled to be evaluated by the Selection Committee at empresas@forocapitalpymes.com. Requirements:
About Foro Capital Pymes: Foro Capital Pymes is an entity that organizes meetings between Spanish SMEs and investors. The most important national and international investors come to the forums (Family Office, Venture Capital, Venture Capital, corporate, etc.) and also financing entities. In the 37 editions held in Madrid and Barcelona they have presented 274 companies and 535 investors have attended. Financing agreements are being closed in each of the forums held. To date, the entity has obtained funds of more than 25 million euros for participating companies. Forum Promoters: MAB, Barcelona Stock Exchange, Madrid Stock Exchange, Keiretsu Forum, Enisa, Chambers of Barcelona and Madrid, Junta Andalucía, Caixa Fórum, ICF, Avalis, among others. |
-
Finance your innovation through non-dilutive funding10:00 - 11:00
-
Start-ups presentations11:00 - 12:00
-
Welcome remarks & institutional inauguration Italica Auditorium12:00 - 13:00
-
Lunch Break13:00 - 14:00
-
Early Stage Financing & impact investment in biotechnology14:15 - 15:15
-
Start-ups presentations15:15 - 15:45
-
Plenary Session - Italica Auditorium Marta Alarcón Riquelme, Head-Area of Medical Genomics (Genyo)15:45 - 16:15
-
Big-Pharma presentations16:15 - 17:00
-
Corporate vs Private VC: differences, similarities & sinergies17:00 - 18:00
-
Welcome Reception (Location: The Real Venta de Antequera. Avenida de Jerez Nº54 , 41014 Sevilla)19:00 - 21:30
-
Is there a way out of the dementia maze?10:45 - 11:45
-
Welcome remarks & institutional inauguration Italica Auditorium12:00 - 13:00
-
Lunch Break13:00 - 14:00
-
Milestones and Current Challenges in Advanced Therapies14:15 - 15:45
-
Plenary Session - Italica Auditorium Marta Alarcón Riquelme, Head-Area of Medical Genomics (Genyo)15:45 - 16:15
-
Biobanks: structures at the service of research16:15 - 17:00
-
Biobanks: structures at the service of research16:15 - 17:00
-
Biobanks: structures at the service of research16:15 - 17:00
-
Biobanks: structures at the service of research16:15 - 17:15
-
Big Data & Biomedical Research17:15 - 18:00
-
Welcome Reception (Location: The Real Venta de Antequera. Avenida de Jerez Nº54 , 41014 Sevilla)19:00 - 21:30
-
Agrobiotechnology forum10:00 - 12:00
-
Welcome remarks & institutional inauguration Italica Auditorium12:00 - 13:00
-
Lunch Break13:00 - 14:00
-
Foodbiotech & Bioprocess14:15 - 15:15
-
Increasing the value of your Asset: considerations for Phase I hybrid trials15:15 - 15:45
-
Plenary Session - Italica Auditorium Marta Alarcón Riquelme, Head-Area of Medical Genomics (Genyo)15:45 - 16:15
-
New therapeutic approaches in ophthalmology16:15 - 17:15
-
Animal Health17:15 - 18:00
-
Welcome Reception (Location: The Real Venta de Antequera. Avenida de Jerez Nº54 , 41014 Sevilla)19:00 - 21:30